Table 3.

Treatment-emergent adverse events over 2 years by system organ class and preferred term reported by ≥5% in any one group (safety population)

	Liraglutide 1.2 mg (N = 251)	Liraglutide 1.8 mg (N = 246)	Glimepiride 8 mg (N = 248)
All adverse events	213(85%)	207(84%)	194(78%)
Gastrointestinal disorders	135(54%)	130(53%)	70(28%)
Constipation	21(8%)	29(12%)	12(5%)
Diarrhoea	44(18%)	48(20%)	23(9%)
Flatulence	4(2%)	13(5%)	5(2%)
Nausea	72(29%)	75(31%)	21(9%)
Vomiting	33(13%)	25(10%)	10(4%)
Cardiac disorders	8(3%)	11(5%)	14(6%)
Eye disorders	15(6%)	14(6%)	16(7%)
General disorders and administration site conditions	42(17%)	51(21%)	39(16%)
Fatigue	8(3%)	13(5%)	9(4%)
Infections and infestations	134(53%)	124(50%)	114(46%)
Bronchitis	15(6%)	9(4%)	11(4%)
Influenza	23(9%)	27(11%)	21(9%)
Nasopharyngitis	23(9%)	16(7%)	18(7%)
Sinusitis	21(8%)	18(7%)	18(7%)
Upper respiratory tract infection	36(14%)	33(13%)	22(9%)
Urinary tract infection	26(10%)	15(6%)	13(5%)
Injury, poisoning and procedural complications	32(13%)	35(14%)	37(15%)
Investigations	23(9%)	31(13%)	25(10%)
Metabolism and nutrition disorders	45(18%)	42(17%)	36(15%)
Musculoskeletal, connective tissue disorders	61(24%)	61(25%)	58(23%)
Arthralgia	11(4%)	6(2%)	15(6%)
Back pain	18(7%)	18(7%)	17(7%)
Pain in extremity	9(4%)	15(6%)	8(3%)
Nervous system disorders	65(26%)	58(24%)	58(23%)
Dizziness	13(5%)	19(8%)	13(5%)
Headache	28(11%)	18(7%)	23(9%)
Psychiatric disorders	24(10%)	28(11%)	16(7%)
Depression	8(3%)	14(6%)	5(2%)
Renal and urinary disorders	13(5%)	11(5%)	15(6%)
Reproductive system and breast disorders	12(5%)	14(6%)	12(5%)
Respiratory, thoracic and mediastinal disorders	23(9%)	42(17%)	36(15%)
Cough	5(2%)	14(6%)	11(4%)
Skin and subcutaneous tissue disorders	26(10%)	31(13%)	20(8%)
Vascular disorders	20(8%)	20(8%)	20(8%)
Hypertension	14(6%)	11(5%)	17(7%)

Data are n (%).